The Cutaneous Connection

In this episode of The Cutaneous Connection, we sat down with Miles Harrison, president and CEO of Conexeu Sciences, along with the company's chief medical officer, Dr. Brian Pilcher. We spoke about the development of an investigational extracellular matrix -based regenerative platform, CXU, that aims to restore tissue architecture rather than simply replace lost volume. 

In this discussion, the executives explore the science behind the technology, its potential applications in wound healing and medical aesthetics, the growing need for regenerative solutions in the era of GLP-1–associated weight loss, and Conexeu's regulatory strategy as it advances toward clinical translation.

In the most recent episode of the Derm Dispatch video series, host Renata Block, DMSCc, MMS, PA-C, a Chicago-based physician assistant, interviewed Kelly Barta, the president and executive director of the International Topical Steroid Awareness Network (ITSAN), to discuss the new ICD-10 code for topical steroid withdrawal and ITSAN's patient registry. 

The ICD-10 code for TSW went through 3 formal reviews with the CDC and a split board vote before receiving final approval, with support from the American Academy of Dermatology. Barta said the designation gives patients a formal diagnosis within the health system for the first time and allows researchers to begin capturing incidence and prevalence data.

In this episode of The Cutaneous Connection, Dermatology Times revisits a recent video episode of the Derm Dispatch show where host Renata Block, DMSc, MMS, PA-C, sits down with Zachary Rubin, MD — allergist, pediatrician, and New York Times bestselling author of All About Allergies — to explore the intersection of dermatology and allergy. Together, they tackle one of the most persistent myths in practice: that food elimination can treat atopic dermatitis.

Dr. Rubin breaks down the difference between IgE-mediated allergic reactions and the complex inflammatory nature of eczema, explains the atopic march, and discusses how understanding the gut-lung-skin axis can empower patients to take charge of their care. The conversation also covers the latest treatment advances — from JAK inhibitors to novel biologics — and touches on indolent systemic mastocytosis and the truth about so-called hypoallergenic dogs. A must-listen for any clinician treating allergic and inflammatory skin disease.

For more content, visit https://www.dermatologytimes.com/

Join Dermatology Times for a conversation with Liza O'Dowd, MD, vice president of immunodermatology and respiratory disease areas at Johnson & Johnson, recorded at the 2026 AAD Annual Meeting. Dr. O'Dowd discusses one-year efficacy and safety data for icotrokinra (Icotyde), the newly approved once-daily oral peptide IL-23 receptor antagonist for moderate to severe plaque psoriasis in adults and adolescents 12 and older.

At 52 weeks, approximately 50% of adult patients achieved total skin clearance, rising to 60% in adolescents enrolled in the LEAD study. Adverse event rates through one year remained within 1.1% of placebo, with no mandatory tuberculosis pre-screening required. Dr. O'Dowd also addresses icotrokinra's anticipated role as a first-line systemic therapy and offers practical reassurance for clinicians considering this novel agent for their patients.

For more content from Dermatology Times, visit https://www.dermatologytimes.com/

In this episode, board-certified dermatologist of US Dermatology Partners, Daniel Walker, MD, FAAD, shares emerging insights into the expanding role of GLP-1 receptor agonists beyond their primary use in diabetes and weight loss, highlighting their promising—yet still investigational—impact on inflammatory skin diseases such as psoriasis and HS. 

In this conversation, identical twin practitioners—dermatologist Amy Spizuoco, DO, FAOCD, and dentist Stacy Spizuoco, DDS,—discuss how dentistry and dermatology intersect in shared patients, from oral lesions and skin conditions to cosmetic collaborations that brighten and rejuvenate smiles “by the skin of your teeth.” 

In this episode, we sat down with Doris Day, MD, a board-certified dermatologist in New York City, who's 25-year long career focuses on longevity aesthetics. She discussed the most common cutaneous concerns among menopausal women, insights from Galderma’s recent menopause survey, and how dermatologists can thoughtfully incorporate conversations about hormonal health into aesthetic consultations. 

In the latest installment of Dermatology Times' video series, the Derm Dispatch, host Renata Block, DMSc, MMS, PA-C, sits down with indolent systemic mastocytosis patient advocate Suki Tipp to examine the clinical, emotional, and financial toll of delayed diagnosis—and the critical role dermatology clinicians can play in recognizing this rare disease earlier.

Now a vocal advocate, Tipp encourages dermatology clinicians to consider systemic mastocytosis in patients presenting with recurrent urticaria, flushing, unexplained brown macules, and systemic symptoms.